Perioperative therapeutic plasma exchange in a patient with rare Factor XIII inhibitor.

Transfus Apher Sci

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States. Electronic address:

Published: June 2023

AI Article Synopsis

  • - Factor XIII deficiency is a rare bleeding disorder that can be serious if inherited; the case discussed involves a 75-year-old man with an acquired Factor XIII inhibitor treated with therapeutic plasma exchange (TPE) due to a kidney mass.
  • - Six daily TPE treatments were administered to reduce bleeding risks prior to and after a kidney biopsy, with coagulation status monitored through tests like thromboelastography (TEG).
  • - While TPE initially decreased the Factor XIII inhibitor titer and allowed for the successful removal of an oncocytoma, the inhibitor re-emerged months later, highlighting that TPE's effects are only temporary.

Article Abstract

Introduction: Factor XIII deficiency is a rare bleeding disorder which could be severe if inherited or less severe if acquired. We report a case of acquired Factor XIII inhibitor in a 75-year-old male with a suspicious left renal mass treated perioperatively with therapeutic plasma exchange (TPE).

Patient And Method: To perform kidney biopsy and ablation of the renal mass, six daily TPE treatments were performed before and after biopsy to minimize bleeding risk because the patient did not respond to drug therapy. Both thromboelastography (TEG) and laboratory-based coagulation tests were performed to assess coagulation status prior to and after TPE.

Results: The biopsy indicated oncocytoma which was removed by surgical procedure. Factor XIII activity remained below 15 % throughout TPE treatments, but Factor XIII inhibitor titer reduced from initial positive value of 1:40 to negative following the third TPE and remained negative through the sixth TPE. Unfortunately, the inhibitor titer was positive at 1:20 in the fifth month and 1:5 in the sixth month during follow-up.

Conclusions: TPE is useful in removing XIII inhibitory factor, but the effects are only short term.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2023.103654DOI Listing

Publication Analysis

Top Keywords

factor xiii
20
xiii inhibitor
12
therapeutic plasma
8
plasma exchange
8
renal mass
8
tpe treatments
8
inhibitor titer
8
factor
6
xiii
6
tpe
5

Similar Publications

A 69-year-old Japanese man developed abdominal pain, purpura, proteinuria, and hematuria while receiving treatment for pulmonary tuberculosis. A skin biopsy revealed IgA-positive leukocytoclastic vasculitis, and a renal biopsy showed IgA-positive mesangial proliferative glomerulonephritis with crescent formation. Based on these findings, we diagnosed IgA vasculitis with nephritis (IgAVN) and initiated treatment.

View Article and Find Full Text PDF

Background: Germline haplodeficiency (RHD) is associated with thrombocytopenia, platelet dysfunction and predisposition to myeloid malignancies. Platelet expression profiling of a RHD patient showed decreased encoding for the A subunit of factor XIII, a transglutaminase that cross-links fibrin and induces clot stabilization. FXIII-A is synthesized by hematopoietic cells, megakaryocytes and monocytes.

View Article and Find Full Text PDF

Establishing the reference intervals of plasma PLG, FXII activity, and FXIII antigen in healthy adults in Guangzhou.

BMC Cardiovasc Disord

January 2025

Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue Central, Guangzhou, 510280, P. R. China.

Objective: To establish the reference intervals of plasma Plasminogen, Factor XII activity, and Factor XIII Antigen in healthy adults in Guangzhou.

Methods: A total of 168 young people (75 males and 93 females, aged 18-65 years) who underwent physical examination in Zhujiang Hospital of Southern Medical University from 2020 to 2022 were recruited. Sysmex CS5100 automatic coagulation analyzer and matching reagents were used to detect Plasminogen.

View Article and Find Full Text PDF

Background: Rare bleeding disorders (RBDs) include fibrinogen (Factor I), prothrombin (Factor II), Factor V(FV), combined Factor V and Factor VIII, Factor VII, Factor X, Factor XI, Factor XII, and Factor XIII deficiencies. This group accounts for 3-5% of all factor deficiencies. Different symptoms may occur, ranging from mild or moderate bleeding to serious and life-threatening bleeding, which may not be related to the factor level.

View Article and Find Full Text PDF

Background: One-third of patients with peritoneal carcinomatosis undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) present alterations in conventional coagulation test results. However, perioperative coagulation has not been systematically investigated in these patients. This study aimed to investigate hemostatic changes in such patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!